Syndax Pharmaceuticals

SNDX49

$16.51arrow_drop_up0.06%$0.01

SNDX49

$16.51

arrow_drop_up0.06%$0.01

Performance History

Key Stats
Open	$16.63
Prev. Close	$16.50
EPS	-3.64
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-

PE Ratio	-

	LOW	HIGH
Day Range	16.30	17.14
52 Week Range	11.21	25.34

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-3.64

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Syndax Pharmaceuticals (SNDX)

Syndax Pharmaceuticals Inc (SNDX) is a clinical-stage biopharmaceutical company that focuses on developing therapies to overcome the challenge of drug resistance in cancer. The company's lead product candidate, entinostat, is an oral, selective inhibitor of class I HDAC enzymes. It is currently being evaluated in multiple clinical trials for the treatment of various types of cancer, including breast, lung, and ovarian cancer.

The stock price history of Syndax Pharmaceuticals Inc (SNDX) has been quite volatile. Over the past year, the stock has witnessed significant fluctuations, with highs and lows ranging from $10 to $30 per share. This volatility can be attributed to market conditions, clinical trial results, and investor sentiment.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Michael A. Metzger M.B.A.
Headquarters: Waltham
Employees: 107
Exchange: NASDAQ

Keep an eye on Syndax Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Syndax Pharmaceuticals 's (SNDX) price per share?

The current price per share for Syndax Pharmaceuticals (SNDX) is $16.51. The stock has seen a price change of $0.01 recently, indicating a 0.06% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Syndax Pharmaceuticals (SNDX)?

For Syndax Pharmaceuticals (SNDX), the 52-week high is $25.34, which is 53.48% from the current price. The 52-week low is $11.22, the current price is 47.21% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Syndax Pharmaceuticals (SNDX) a growth stock?

Syndax Pharmaceuticals (SNDX) has shown an average price growth of -2.69% over the past three years. It has received a score of 54 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Syndax Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Syndax Pharmaceuticals (SNDX) stock price performance year to date (YTD)?

As of the latest data, Syndax Pharmaceuticals (SNDX) has a year-to-date price change of -24.47%. Over the past month, the stock has experienced a price change of -14.06%. Over the last three months, the change has been -20.66%. Over the past six months, the figure is -17.78%. Looking at a longer horizon, the five-year price change stands at 127.41%.

help

Is Syndax Pharmaceuticals (SNDX) a profitable company?

Syndax Pharmaceuticals (SNDX) has a net income of -$209.36M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -716.62% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$229.95M. Furthermore, the EBITDA is -$321.2M.

help

What is the market capitalization of Syndax Pharmaceuticals (SNDX)?

Syndax Pharmaceuticals (SNDX) has a market capitalization of $1.41B. The average daily trading volume is 16.49, indicating the stock's liquidity and investor engagement.